Scientists are developing a new MRI-based test that could spare thousands of cancer patients from aggressive radiotherapy treatment.
The pioneering imaging technology works by “colour-coding” oxygen starved cancerous tissue on scans and could be used to help clinicians identify which patients with HPV positive throat cancer can receive lower doses of radiotherapy that provide the same treatment benefit while reducing long-term side effects.
The technique, known as HYPOXiMAP, is being developed by researchers at The Institute of Cancer Research, London, in collaboration with University College London and The University of Manchester.
Colour-coding treatment-resistant cancer
The technique uses advanced MRI to reveal pockets of hypoxia — areas of low oxygen within tumours that are known to make cancer cells more resistant to radiotherapy.
HYPOXiMAP provides this information as a vivid, intuitive colour map. Blue areas reveal hypoxic, treatment resistant tissue, while yellow shows well oxygenated regions that typically respond well to radiotherapy. Being able to provide this information in real-time will one day allow smart radiotherapy systems that can automatically adjust themselves to provide gentler treatment whenever appropriate.
Reducing the long-term impact of radiotherapy
There are around 13,000 new cases of head and neck cancer in the UK every year. Rates of HPV positive oropharyngeal (throat) cancer are increasing sharply, with a 47 per cent rise in cases between 2013 and 2019.
Around 70 per cent of patients are treated with radiotherapy. However, the standard high dose used frequently results in long term side effects, such as swallowing difficulties, dry mouth, taste changes and persistent fatigue. More than half of patients experience significant long-term side effects.
Finding the patients who need less treatment
The biological importance of hypoxia in solid tumours has been recognised for decades, with links established as early as the 1950s. This has driven scientific efforts to explore whether some patients — particularly those whose tumours show very low levels of hypoxia — could safely receive reduced radiation doses.
Studies in the United States have shown that a highly specialised form of PET scanning can identify well oxygenated tumours suitable for radiotherapy dose reduction. However, these scans are very costly and available only in a limited number of research centres in the UK, making them unsuitable for widespread NHS use or large-scale trials.
Since MRI scanners are already standard equipment in hospitals across the NHS, HYPOXiMAP is a more accessible alternative.
The research team has shown that the MRI based method can reliably distinguish oxygen rich from oxygen poor HPV positive throat cancers and can also monitor changes in tumour hypoxia during radiotherapy — providing clinicians with real-time feedback on how treatment is progressing.
Advancing imaging into clinical use
A £1.63 million award from Cancer Research UK will now fund the final stage of development required to prepare HYPOXiMAP for use in large clinical studies.
The CRUK-funded four-year programme of work unites academic, clinical and industry partners to advance HYPOXiMAP imaging towards clinical use. Over the next phase of work, the team will refine the imaging process using artificial intelligence (AI) to improve the speed, accuracy and consistency of tumour oxygenation measurements.
To ensure the technology can be used in larger clinical trials, the programme includes a prospective, multi-centre study managed by the ICR’s Clinical Trials and Statistics Unit (ICR-CTSU) to test how consistently HYPOXiMAP performs across different hospitals and MRI scanners.
These results, alongside findings from earlier work, will be used to evaluate strategies for adapting radiotherapy treatment based on HYPOXiMAP imaging, supporting future clinical trials and helping bring the technology into routine care.
‘Protecting quality of life without sacrificing cure rates’
In the future, oxygen-enhanced imaging could also help identify patients who might benefit from immune checkpoint inhibitor drugs, which are known to be less effective in hypoxic tumours.
Professor James O’Connor Professor of Quantitative Biomedical Imaging at The Institute of Cancer Research, London, and Professor of Radiology at The University of Manchester, said: “HYPOXiMAP represents the culmination of 15 years of work to turn MRI into a tool that can show us exactly where low oxygen, treatment resistant cancer cells are located, this technology has the potential to transform how we tailor radiotherapy for patients.
“For those with HPV positive throat cancer and well oxygenated tumours, this technique could help us safely reduce treatment intensity — protecting quality of life without sacrificing cure rates. This new funding allows us to take the final steps to bring this technology into clinical trials and, ultimately, into the hands of clinicians across the NHS.”
Professor Gary Zhang, Professor of Computational Imaging at University College London (UCL) and a co-director of UCL Hawkes Institute, said: “This technology pioneered by Professor O’Connor can make a real difference in the care of many cancer patients. This new funding allows us to harness recent advances to AI to help make this incredible technology even more accessible, so more patient can benefit.”
Professor Kevin Harrington, Head of the Division of Radiotherapy and Imaging at The Institute of Cancer Research, London, said: “For decades, we have known that low oxygen levels inside tumours can influence how cancer responds to therapy, but clinicians have lacked a practical way to visualise this biology in everyday practice.
“By translating that understanding into a precise and accessible MRI technique, this technology has the potential fundamentally to change how radiotherapy is planned for people with HPV-positive throat cancer. It brings us closer to truly personalised treatment — ensuring patients receive the intensity of therapy they need, while avoiding unnecessary side effects.”
Director of Research at Cancer Research UK, Dr Catherine Elliott, said: “Cancer Research UK-funded scientists have been at the forefront of developments in radiotherapy for decades. Thanks to advances in research, people today are benefiting from radiotherapy which kills cancer cells effectively, whilst minimising damage to healthy tissue nearby.
“The HYPOXiMAP project aims to map those oxygen-rich areas where tumours are most susceptible to beams of radiation. This method could lead us to a hyper-targeted approach to radiotherapy, which substantially reduces long-term side-effects. Ultimately, research like this will move us towards a world where people live longer, better lives, free from the fear of cancer.”






